AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04139876 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LigaSure Hemorrhoidectomy
Description: Patient is operated in the lithotomy position. The main haemorrhoidal (H) masses are identified and delineated. The H are prolapsed out from the anal canal with Allis clamps or similar pick up forceps. Tension is applied to visualise the junction between the nodule and the mucosal wall (internal) or the perianal tissue (external). A small V-shaped anodermal seal is performed by applying the LigaSure (LS) forceps close to the edge of each pile. The seal is then transacted with scissors along the line of coagulum. Care should be taken to limit the amount of tissue removed to minimize the stricture risk. Repeated applications of the device are performed and the excision is continued into the anal canal, lifting the pile from the internal anal sphincter to the level of the vascular pedicle that is finally sealed by LS and divided.
Study NCT03296046 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood test
Description: 30 ml
Study NCT01110200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVAIR DISKUS 250/50 mg BID
Description: Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.
Study NCT01110200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SEREVENT 50 mcg BID
Description: Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
Study NCT02678858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Social Cognitive and Behavioral Skills Therapy
Description: The Integrated Social Cognitive and Behavioral Skills Therapy (ISST) is a newly developed treatment program. It is based on the Training of Affect Recognition (Wölwer et al. 2005) and common social skills trainings, which are combined in an integrated rather than a sequenced manner. ISST uses both repeated practice and strategy-based training, and consists of 12 individual sessions, 5 group sessions and 1 individual final session over a period of 6 months.
Study NCT02678858 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neurocognitive Remediation Therapy
Description: The Neurocognitive Remediation Program (NCRT) is based on a neurocognitive training already used as active control condition in our earlier studies (Wölwer et al. 2005, Klingberg et al. 2011). The present version of NCRT is matched in dose, mode and scheme of application to the ISST, but differs from the ISST regarding targeted cognitive domains and preferred training strategy (predominantly drill and practice based). The NCRT provides the same amount of group interaction and companionship as well as the same amount of guided community activity as in the ISST, but is structured in such a way that interactional behavior is secondary (e.g. by competition-like tasks rather than cooperative tasks). Thus therapeutic attention and commitment are held constant across study conditions.
Study NCT03881150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive assessment
Description: Includes evaluation about physical activity, diet, tobacco consumption, overweight/obesity, blood pressure, self-efficacy, and medications. Additionally, levels of lipids and glycaemia will be reviewed from clinical chart.
Study NCT03881150 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive assessment
Description: Includes evaluation about physical activity, diet, tobacco consumption, overweight/obesity, blood pressure, self-efficacy, and medications. Additionally, levels of lipids and glycaemia will be reviewed from clinical chart.
Study NCT03881150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Physical activity, diet, smoking, and medication compliance counseling will be provided by the physiotherapist across exercise sessions, using a self-efficacy approach. A booklet was designed in order to support the individual counseling.
Study NCT03881150 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group education
Description: Group education sessions about physical activity, diet, smoking, and medication compliance (without individual counseling), as actually performed in each center.
Study NCT03881150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise sessions in hybrid program
Description: 10 supervised exercise sessions over 4-6 weeks of aerobic and resistance training will ensue, supervised by a physiotherapist. Exercise sessions are 10 minutes in duration at the beginning of the program, and are progressed to 60 minutes by the end as tolerated.~Intensity of exercise will be moderate.
Study NCT03881150 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise sessions in standard program
Description: 18-22 supervised exercise sessions are delivered over the 8-12 week program. These sessions include aerobic and resistance training and a similar progression of duration as the experimental group.~Intensity of exercise will be moderate.
Study NCT03881150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transition to unsupervised phase
Description: After 4-6 weeks with face-to-face exercise sessions in hybrid program, all patients will be monitored through mobile technology. Delivery methods will include voice calls biweekly, and text messaging three per week through to 10-12 weeks from program initiation. The content will promote physical activity, healthy diet, and medication adherence.
Study NCT03146533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2/day IV for 3 days.
Study NCT03146533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8g/m2/day IV for 2 days.
Study NCT03146533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CART
Description: CD19 CART cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
Study NCT02301403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: 8 weeks of nicotine patch
Study NCT02301403 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: in-person counseling and quitline counseling
Description: a single brief, in-person counseling session plus a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), for counseling, including the QUITNOW app and the Website
Study NCT02301403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preparation Nicotine Mini-Lozenges
Description: Nicotine lozenge prior to attempting to quit smoking
Study NCT02301403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination NRT (nicotine patch + nicotine mini-lozenges)
Description: 26 weeks of combination NRT as part of a quit smoking attempt
Study NCT02301403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive In-Person Cessation Counseling
Description: three 20-min In-person Cessation Counseling sessions
Study NCT02301403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Maintenance Counseling Calls
Description: 8 Maintenance-phase smoking cessation counseling sessions
Study NCT02301403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Adherence Calls
Description: 11 brief, automated calls reminding them to use their medications properly
Study NCT01221428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells
Description: Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells(2\*10/7),one week later,conduct intervention operation to inject mesenchymal stem cells to mesenteric artery(1\*10/7).
Study NCT02526550 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated chimeric Japanese Encephalitis vaccine
Description: 0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh
Study NCT02526550 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Hepatitis A vaccine
Description: 0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh
Study NCT01716572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Description: Intravenous 250 mg of erythromycin, single-dose, 30 minutes before the endoscopy
Study NCT01716572 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric lavage
Description: gastric lavage by nasogastric tube with 1 liter of saline before the endoscopy
Study NCT03580421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ambulatory surgery
Description: total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy
Study NCT03580421 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard surgery
Description: total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy
Study NCT03984058 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle Intervention
Description: A lifestyle intervention program adapted from the Diabetes Prevention Program (DPP). Study participants will start lifestyle intervention on the day of initiating PAP therapy. The 3-month program will be followed: Patient-facing Online Platform: The program will be accessible to study participant via the Web or a Web application available for the Android and iOS devices. Behavioral Weight Loss Goals and Lessons: The program begins with an introductory session that presents the basic goals for the program followed by 12 weekly multimedia lessons. Submission of self-monitoring data: Participants will submit daily weight, caloric intake, and physical activity minutes at least weekly to the study website for 12 weeks. Automated Feedback: In response to the self-monitoring data, participants receive a weekly automated message that compares participants' self-reported values to participants' goals for weekly and overall weight loss, caloric intake, and physical activity minutes.
Study NCT03448588 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: detection of serum selenium
Description: For this case-control study, no intervention will be administered to participants, only serum sample will be collected for selenium assessment
Study NCT00184145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMDR (Eye Movement Desensitization and Reprocessing)
Description: Psychotherapy which is approved for PTSD.
Study NCT00184145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Description: All participants in the study received exposure therapy som second treatment. Exposure therapy is the therapy of choice for animal phobia.
Study NCT00139477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, 250mg by mouth twice a day with meals will be started and if tolerated increased to 500mg twice a day in 3 days in those less than 12 years old and titrated further to 1000mg twice a day if tolerated.
Study NCT00139477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin, 250mg by mouth twice a day with meals will be started and if tolerated increased to 500mg twice a day in 3 days in those less than 12 years old and titrated further to 1000mg twice a day if tolerated.
Study NCT00139477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary modification with caloric restriction
Description: The life style intervention changes will include a hypocaloric diet representing at least a 500 kcal/day reduction based on their dietary histories and Resting Energy Expenditure (REE) determined by the initial calorimetry.
Study NCT00139477 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary modification with caloric restriction
Description: The life style intervention changes will include a hypocaloric diet representing at least a 500 kcal/day reduction based on their dietary histories and Resting Energy Expenditure (REE) determined by the initial calorimetry.
Study NCT00139477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Establishment of exercise protocol
Description: Participants will attend the Fitness Center 3 times per week and supervised by an exercise technician or exercise specialist. Exercise will be individually prescribed for each participant based on their functional abilities. Exercise will consist of 5-10 minutes for warm up and stretching, followed by 15-30 minutes of cardiovascular exercise (i.e. treadmill, bicycle ergometer, rower, nustep, etc), 10-20 minutes of strength training (supervised using weight stack equipment), and 5-10 minutes of cool down and stretching. As children typically do not need an exercise prescription based on heart rate, we will familiarize them with perceived exertion scales and monitor that they are exercising in the moderate to hard range of perception of effort. Participants will be started at 15 minutes of cardiovascular exercise and 10 minutes of strength training exercise, progressing by 2-3 minutes every week until 30 and 20 minutes is achieved for each respectively.
Study NCT00139477 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Establishment of exercise protocol
Description: Participants will attend the Fitness Center 3 times per week and supervised by an exercise technician or exercise specialist. Exercise will be individually prescribed for each participant based on their functional abilities. Exercise will consist of 5-10 minutes for warm up and stretching, followed by 15-30 minutes of cardiovascular exercise (i.e. treadmill, bicycle ergometer, rower, nustep, etc), 10-20 minutes of strength training (supervised using weight stack equipment), and 5-10 minutes of cool down and stretching. As children typically do not need an exercise prescription based on heart rate, we will familiarize them with perceived exertion scales and monitor that they are exercising in the moderate to hard range of perception of effort. Participants will be started at 15 minutes of cardiovascular exercise and 10 minutes of strength training exercise, progressing by 2-3 minutes every week until 30 and 20 minutes is achieved for each respectively.
Study NCT00482989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI 545
Description: MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.~Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks.
Study NCT00482989 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.~Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks.
Study NCT00830297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulatard (long-acting insulin)
Description: In group No.1 (study arm 1 (=A)), patients will be treated with long-acting insulin (Insulatard) as soon as the glucose-level before supper surpasses 140 mg/dl. The normoglycemic goal in this group will be from 110 to 120 mg/dl.
Study NCT00830297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: In group No.2 (study arm 2 (=B)), patients will be treated conventionally according to the decisions taken by the physicians on the ward. The following suggestions will be brought to the attention of the ward in order to standardize the treatment of the patients in study arm B: 1. Treatment in this group should be initiated if the fasting glucose level surpasses the renal glucose threshold, i.e. 180 mg/dl. 2. As the proposed life-style modifications for the treatment of NODAT1 are not feasible during this very early post-transplant phase, the basis of the conventional therapy will be proposed to be sulfonyl urea drugs (i.e. Gliclazide - Diamicron®, 30 mg, not more than twice daily). 3. Short-acting insulin will be strongly recommended to be used for corrections of capillary blood glucose levels above 250 mg/dl.
Study NCT03387878 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intermittent Catheter
Description: Intermittent urinary catheter for bladder drainage
Study NCT04220476 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)
Description: Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. They will undergo tumor Immunogenic-SBRT(I-SBRT) days 1-12 (+/-2 days, to enable inclusion of holidays). During the week preceding day 1, they will undergo simulation and planning for radiotherapy. Each oligometastatic lesion will be treated with I-SBRT every 48 hours. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions
Study NCT04220476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5Mg Tab
Description: All patients start standard therapy with oral letrozole (Femara), day 1 of the study.
Study NCT04220476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib 125mg
Description: Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.
Study NCT02163603 — intervention group
Intervention type: PROCEDURE
Intervention: Pelvic osteotomy
Study NCT04073524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature-Body-Mind-Community
Description: The Nature-Body-Mind-Community (NBMC) approach has been developed in a pilot project over 2014-2018. The 'Wild man Programme' consists of the following main elements: 1. Nature environments and nature experiences, 2. Mind relaxation and meditation, 3. Body awareness and 4. Fire talks, storytelling and community spirit.
Study NCT04073524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual consist of the rehabilitation offered by the hospital or municipality for the specific condition e.i. cancer, diabetes, COPD, anxiety, depression and stress
Study NCT04073524 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Treatment as usual consist of the rehabilitation offered by the hospital or municipality for the specific condition e.i. cancer, diabetes, COPD, anxiety, depression and stress
Study NCT02267317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eritoran
Description: Pharmacologic inhibitor of TLR4 receptors.
Study NCT02267317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D5W
Description: 5% Dextrose Water = Vehicle
Study NCT03934099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC350189 formulated capsule
Description: Xanthine Oxidase Inhibitor
Study NCT03934099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT02849730 — intervention group
Intervention type: DEVICE
Intervention: Fentanyl/ropivacaine based Epi-PCA
Description: Fentanyl and ropivacaine was diluted and administered to the patients according to the clinician's determination. The clinician decided dose, infusion rate, bolus dose, lockout time and total amount of drug mixed in the Epi-PCA.
Study NCT03739034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Medicine
Description: Treatment modalities consist of encouraging a plant based, whole food diet, physical activity, stress management, healthy sleep, control of unhealthy habits.
Study NCT02200809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-guided focal laser ablation
Study NCT04074161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Dose gradually increased to 2.4 mg administered once weekly for 68 weeks
Study NCT04074161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Administered once weekly for 68 weeks
Study NCT04074161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Dose gradually increased to 3.0 mg administered once daily for 68 weeks
Study NCT04074161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (liraglutide)
Description: Administered once daily for 68 weeks
Study NCT01689532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg
Description: Sirukumab 100 mg subcutaneous (SC) injection, at Weeks 0, 2, and every 2 weeks through Week 52.
Study NCT01689532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg
Description: Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52.
Study NCT01470170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal Saline (placebo comparator) was given in equivalent amount of alfentanil dosage in each arm, for double blinded purpose.
Study NCT01689532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Between sirukumab injections, placebo SC at Weeks 2, 6, and every 4 weeks through Week 52.
Study NCT03936790 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ropivacaine
Description: In case of successful spinal anaesthesia, the dose of spinally administered ropivacaine will decrease by 0.375 mg for the next participant.In case of unsuccessful spinal anaesthesia, the dose of spinally administered ropivacaine will increase by 0.375 mg for the next participant.
Study NCT03936790 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fentanyl
Description: A fix dose of fentanyl (15 mcg) will be co-administered spinally to all participants.